SG Americas Securities LLC Grows Position in Aurinia Pharmaceuticals Inc $AUPH

SG Americas Securities LLC raised its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 69.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 136,224 shares of the biotechnology company’s stock after purchasing an additional 55,903 shares during the period. SG Americas Securities LLC owned 0.10% of Aurinia Pharmaceuticals worth $2,173,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of AUPH. Arrowstreet Capital Limited Partnership lifted its stake in shares of Aurinia Pharmaceuticals by 213.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock valued at $37,283,000 after buying an additional 2,297,903 shares in the last quarter. Marshall Wace LLP raised its holdings in Aurinia Pharmaceuticals by 1,272.5% during the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock valued at $16,389,000 after acquiring an additional 1,375,072 shares during the period. Two Sigma Investments LP raised its holdings in Aurinia Pharmaceuticals by 728.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock valued at $14,819,000 after acquiring an additional 1,179,219 shares during the period. Qube Research & Technologies Ltd lifted its position in shares of Aurinia Pharmaceuticals by 45.1% during the second quarter. Qube Research & Technologies Ltd now owns 1,242,512 shares of the biotechnology company’s stock worth $10,524,000 after acquiring an additional 386,364 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Aurinia Pharmaceuticals by 63.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,219,451 shares of the biotechnology company’s stock worth $13,475,000 after acquiring an additional 471,338 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 516,439 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $13.99 per share, with a total value of $7,224,981.61. Following the completion of the acquisition, the director owned 11,845,939 shares of the company’s stock, valued at $165,724,686.61. This trade represents a 4.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 12.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $17.25.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $15.61 on Friday. The company has a market capitalization of $2.08 billion, a PE ratio of 7.50 and a beta of 1.51. Aurinia Pharmaceuticals Inc has a 52-week low of $6.82 and a 52-week high of $16.54. The business’s fifty day moving average is $14.51 and its 200 day moving average is $14.32. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.76 and a current ratio of 5.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, February 26th. The biotechnology company reported $1.53 EPS for the quarter, topping the consensus estimate of $0.21 by $1.32. Aurinia Pharmaceuticals had a return on equity of 27.47% and a net margin of 101.46%.The business had revenue of $77.11 million during the quarter, compared to analysts’ expectations of $74.70 million. On average, equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.